Sign up to save your podcasts
Or
Share Nuformix Plc, EMA Backs Orphan Status for NXP002 in Pulmonary Fibrosis Breakthrough
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Nuformix Plc, EMA Backs Orphan Status for NXP002 in Pulmonary Fibrosis Breakthrough
Nuformix Plc (LON:NFX) just secured a significant regulatory milestone. Europe’s EMA has issued a positive opinion granting orphan drug designation for its lead asset NXP002 (Tranilast) in idiopathic pulmonary fibrosis.
In this interview, Executive Director Dr Dan Gooding outlines how this validation not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial edge with 10 years of market exclusivity and accelerated development support. Investors will want to hear how this development positions Nuformix for partnerships, progress in the US, and wider clinical momentum.
#Nuformix #Tranilast #NXP002 #IdiopathicPulmonaryFibrosis #IPF #BiotechNews #DrugDevelopment #EMA #OrphanDrugDesignation #PharmaInvesting #LifeSciences #UKBiotech
https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l
View all episodes
By DirectorsTalkNuformix Plc (LON:NFX) just secured a significant regulatory milestone. Europe’s EMA has issued a positive opinion granting orphan drug designation for its lead asset NXP002 (Tranilast) in idiopathic pulmonary fibrosis.
In this interview, Executive Director Dr Dan Gooding outlines how this validation not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial edge with 10 years of market exclusivity and accelerated development support. Investors will want to hear how this development positions Nuformix for partnerships, progress in the US, and wider clinical momentum.
#Nuformix #Tranilast #NXP002 #IdiopathicPulmonaryFibrosis #IPF #BiotechNews #DrugDevelopment #EMA #OrphanDrugDesignation #PharmaInvesting #LifeSciences #UKBiotech
https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l